Liminatus Pharma 10-Q: Going Concern Doubt, Material Weaknesses, Nasdaq Deadline Sept 3
LIMN sits 38% above its 52-week low of $0.095 on light trading volume (0.3× avg).
Summary
Liminatus Pharma's 10-Q discloses going concern doubt, material weaknesses, and a September 3 Nasdaq compliance deadline, while detailing the InnocsAI acquisition and a cash balance of $3.0 million.
Key Events · Earnings and Guidance · LIMN
-
Going Concern Doubt
Management concluded there is substantial doubt about the company's ability to continue as a going concern for one year after the financial statement issuance date.
-
Material Weaknesses
Disclosed material weaknesses in internal control over financial reporting, including lack of a formalized control environment and inadequate segregation of duties.
-
Nasdaq Compliance Deadline
Nasdaq Hearings Panel granted an extension to September 3, 2026 to demonstrate a $1.00 closing bid price for at least ten consecutive trading days.
-
InnocsAI Acquisition Completed
On July 2, 2026, the company issued 11,188,729 shares of common stock and 158,881.1271 shares of Series A Preferred Stock to complete the InnocsAI acquisition.
Analysis · LIMN · Life Sciences
The quarterly report reveals management's substantial doubt about the company's ability to continue as a going concern, material weaknesses in internal controls, and a September 3 deadline to regain Nasdaq compliance. Cash of $3.0 million at June 30, 2026, combined with a $2.5 million net loss for the first half, underscores the liquidity strain. The company completed the InnocsAI acquisition on July 2, 2026, issuing 11.2 million common shares and 158,881 shares of Series A Preferred Stock, which adds significant potential dilution. The Nasdaq Hearings Panel granted a brief extension to September 3, 2026 to demonstrate a $1.00 closing bid price for ten consecutive trading days, a critical near-term milestone.
At the time of this filing, LIMN was trading at $0.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.4M. The 52-week trading range was $0.10 to $4.85. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.